Le Lézard
Classified in: Health
Subjects: FDA, MAT

/C O R R E C T I O N -- Honest Globe/


In the news release, Elixicure CBD-Infused Pain Relief Product Receives FDA Certification, issued 29-Jan-2020 by Honest Globe over PR Newswire, we are advised by the company that the headline should read "Elixicure CBD-Infused Pain Relief Product Listing Receives FDA Certification" rather than "Elixicure CBD-Infused Pain Relief Product Receives FDA Certification" as originally issued inadvertently. The 5th paragraph, sentences 3-5, should read "As part of this process Elixicure consulted and adopted quality standards and procedures set by BSCG. BSCG is the standard in testing for third-party certification that ensures products meet quality specifications and are not contaminated with drugs or agents that can lead to health concerns or positive drug tests. Through repeated inspection and ongoing testing, Elixicure's product and manufacturing facility have consistently proven to meet all necessary requirements for maintaining Product and Facility GMP certifications." rather than "As part of this process Elixicure consulted and adopted quality standards and procedures set by NSF International, which sets international public health standards and certification programs that help protect the world's food, water, consumer products and the environment. Through repeated inspection and ongoing testing, Elixicure's product and manufacturing facility have consistently proven to meet all necessary requirements for maintaining Product and Facility GMP certifications." as originally issued inadvertently. The 7th paragraph, sentence 1 should read "Elixicure is certified by Banned Substance Control Group (BSCG), and thus safe for use by athletes at all competitive levels." rather than "Elixicure is also certified by Banned Substance Control Group (BSCG), and thus safe for use by athletes at all competitive levels." as originally issued inadvertently. The complete, corrected release follows:

Elixicure CBD-Infused Pain Relief Product Listing Receives FDA Certification

SANTA ANA, Calif., Jan. 29, 2020 /PRNewswire/ -- Elixicure's Over-The-Counter Drug Registration has been Certified by the U.S. Food and Drug Administration (FDA) for its Elixicure CBD-Infused Pain Relief products following a successful year-long process, announced Elixicure Chief of Business Development Yaniv Kotler. This marks the very first, and currently only, Over-The-Counter (OTC) Topical drug with Cannabidiol (CBD) to be registered and certified to date.

Elixicure is an all-natural, non-addictive pain relief cream developed to help reduce inflammation, swelling, aches and pains. The product contains Cannabidiol (CBD) extract, one of the main active chemical compounds naturally found in the hemp plant and contributing to the beneficial medicinal qualities of hemp. Unlike THC, hemp CBD extract does not make you feel "high".

"We are ecstatic to announce that Elixicure's Registration has been Certified by the FDA," said Kotler. "This is a major milestone in our commitment to quality, and offering customers healthier options for pain relief using effective natural products, as an alternative to opioids and other dangerous pharmaceuticals."

Elixicure is manufactured by Honest Globe, developers of luxury cosmetic, health and beauty products. The company's products are made with naturally-derived ingredients, using certified industry-standard manufacturing processes.

Kotler said Elixicure and Honest Globe set out to comply with the most rigid standards set by the FDA, which established Good Manufacturing Practices (GMP's) for the Food, Beverage, Drug, Cosmetic, Medical Device and Supplement industries. GMP Guidelines outline and identify minimum operating and testing requirements and standards that manufacturers must meet to ensure products are consistent in quality from batch to batch and safe for human use or consumption. GMP's are ensured through effective quality management systems. As part of this process Elixicure consulted and adopted quality standards and procedures set by BSCG. BSCG is the standard in testing for third-party certification that ensures products meet quality specifications and are not contaminated with drugs or agents that can lead to health concerns or positive drug tests. Through repeated inspection and ongoing testing, Elixicure's product and manufacturing facility have consistently proven to meet all necessary requirements for maintaining Product and Facility GMP certifications.

"Customer trust is important to us," Kotler said. "Unlike so many companies that market CBD and CBD products, our business model has always been driven by quality and compliance, which is verified by 3rd party certifiers. This certification requires us to vet our processes, our equipment and systems, our vendors and suppliers, and conduct batch-by-batch testing to ensure quality."

Elixicure is certified by Banned Substance Control Group (BSCG), and thus safe for use by athletes at all competitive levels. BSCG offers a complete suite of certification, testing and GMP compliance services to the dietary supplement and natural product communities. Through their ongoing compliance process, which includes random testing of product on the shelf, BSCG certifies the product contains no heavy metals, microbials, no THC, while certifying presence of the active ingredients and amounts CBD present. With a foundation in anti-doping and sport drug testing, BSCG offers the Olympic standard in analytical testing to finished product brands, ingredient suppliers, and manufacturing facilities.

More product and company information is available at https://elixicure.com and https://honestglobe.com.

IMAGE DOWNLOAD

SOURCE Honest Globe


These press releases may also interest you

at 06:00
Zymeworks Inc. , a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced the appointment of Dr. Neil Gallagher to...

at 05:45
The "Distribution Deals in Diagnostics 2016 to 2024" report has been added to  ResearchAndMarkets.com's offering. Distribution Deals in Diagnostics provides a detailed understanding and analysis of how and why companies enter distribution...

at 05:10
Neurology Devices: Global Markets is basically a detailed study or report about the worldwide market for medical tools used in treating neurological conditions. These devices could be anything from equipment that helps stimulate the nervous system to...

at 05:04
Sirnaomics Ltd. (the "Company"; together with its subsidiaries, "Sirnaomics" or the "Group"; stock code: 2257), a leading biopharmaceutical company engaged in the discovery and development of advanced RNAi therapeutics, has announced its audited...

at 04:28
GymNation, the homegrown UAE fitness brand, has today announced that due to unprecedented growth, it is reaching capacity across its 12 UAE gym locations and diversifying into a new market, brewing up a storm with the launch of its first-ever branded...

at 04:00
Cancer spreads from its primary tumor to other parts of the body via blood or the lymphatic system in a process termed 'metastasis'. This usually represents an advanced stage in the disease's progression and tends to be fatal. Therefore, preventing...



News published on and distributed by: